These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 20039931)

  • 1. High-dose tirofiban with enoxaparin and inflammatory markers in high-risk percutaneous intervention.
    Walters DL; Ray MJ; Wood P; Perrin EJ; Bett JH; Aroney CN
    Eur J Clin Invest; 2010 Feb; 40(2):139-47. PubMed ID: 20039931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attenuation of platelet reactivity by enoxaparin compared with unfractionated heparin in patients undergoing haemodialysis.
    Aggarwal A; Whitaker DA; Rimmer JM; Solomon RJ; Gennari FJ; Sobel BE; Schneider DJ
    Nephrol Dial Transplant; 2004 Jun; 19(6):1559-63. PubMed ID: 15034156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial.
    Valgimigli M; Percoco G; Barbieri D; Ferrari F; Guardigli G; Parrinello G; Soukhomovskaia O; Ferrari R
    J Am Coll Cardiol; 2004 Jul; 44(1):14-9. PubMed ID: 15234398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unfractionated heparin but not enoxaparin causes delayed plasma PAI-1 depletion in hemodialysis patients: a prospective study.
    Naumnik B; Pawlak K; Mys'liwiec M
    Clin Appl Thromb Hemost; 2009 Feb; 15(1):84-91. PubMed ID: 17895513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of upstream tirofiban versus downstream tirofiban on myocardial damage and 180-day clinical outcomes in high-risk acute coronary syndromes patients undergoing percutaneous coronary interventions.
    Liu T; Xie Y; Zhou YJ; Li YP; Ma HY; Guo YH; Liu YY; Zhao YX; Shi DM
    Chin Med J (Engl); 2009 Aug; 122(15):1732-7. PubMed ID: 19781316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct yet complementary mechanisms of heparin and glycoprotein IIb/IIIa inhibitors on platelet activation and aggregation: implications for restenosis during percutaneous coronary intervention.
    Day JR; Malik IS; Weerasinghe A; Poullis M; Nadra I; Haskard DO; Taylor KM; Landis RC
    Heart; 2004 Jul; 90(7):794-9. PubMed ID: 15201252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
    Cohen M
    J Invasive Cardiol; 2000 Dec; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of unfractionated and low molecular weight heparins on plasma levels of hemostatic factors in patients with acute coronary syndromes.
    Vila V; Martínez-Sales V; Réganon E; Peris E; Perez F; Ruano M; Aznar J
    Haematologica; 2001 Jul; 86(7):729-34. PubMed ID: 11454528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of enoxaparin versus heparin during elective percutaneous coronary intervention performed with either eptifibatide or tirofiban (the ACTION Trial).
    Madan M; Radhakrishnan S; Reis M; Paradiso-Hardy FL; Godin-Edgecombe M; Sparling C; Phillips AM; Shanmugasegaram S; Fort S; Naqvi SZ; Cohen EA
    Am J Cardiol; 2005 Jun; 95(11):1295-301. PubMed ID: 15904632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
    White HD; Kleiman NS; Mahaffey KW; Lokhnygina Y; Pieper KS; Chiswell K; Cohen M; Harrington RA; Chew DP; Petersen JL; Berdan LG; Aylward PE; Nessel CC; Ferguson JJ; Califf RM
    Am Heart J; 2006 Dec; 152(6):1042-50. PubMed ID: 17161049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of tirofiban on acute systemic inflammatory response in elective percutaneous coronary interventions.
    Akbulut M; Ozbay Y; Gundogdu O; Dagli N; Durukan P; Ilkay E; Arslan N
    Curr Med Res Opin; 2004 Nov; 20(11):1759-67. PubMed ID: 15537476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease.
    Chen JL; Chen J; Qiao SB; Guo YL; Wu YJ; Dai J; Yuan JQ; Qin XW; Yang YJ; Gao RL
    Chin Med J (Engl); 2006 Mar; 119(5):355-9. PubMed ID: 16542576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial.
    Mehta SR; Granger CB; Eikelboom JW; Bassand JP; Wallentin L; Faxon DP; Peters RJ; Budaj A; Afzal R; Chrolavicius S; Fox KA; Yusuf S
    J Am Coll Cardiol; 2007 Oct; 50(18):1742-51. PubMed ID: 17964037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enoxaparin but not unfractionated heparin causes a dose-dependent increase in plasma TGF-beta 1 during haemodialysis: a cross-over study.
    Naumnik B; Borawski J; Pawlak K; Mysliwiec M
    Nephrol Dial Transplant; 2007 Jun; 22(6):1690-6. PubMed ID: 17389624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tirofiban optimizes platelet inhibition for immediate percutaneous coronary intervention in high-risk acute coronary syndromes.
    Ivandic BT; Kurz K; Keck F; Staritz P; Lehrke S; Katus HA; Giannitsis E
    Thromb Haemost; 2008 Oct; 100(4):648-54. PubMed ID: 18841288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different effects of enoxaparin and unfractionated heparin on some thrombogenesis markers during hemodialysis: a cross-over study.
    Naumnik B; Pawlak K; Myśliwiec M
    Thromb Res; 2009 Feb; 123(4):631-6. PubMed ID: 18234290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet inhibition by increased tirofiban dosing during primary coronary angioplasty for ST elevation myocardial infarction.
    Kralisz P; Dobrzycki S; Nowak K; Kochman W; Gajewska-Bachórzewska H; Gugała K; Mezyński G; Prokopczuk P; Zuk J; Korecki J; Poniatowski B; Musiał W
    Kardiol Pol; 2004 May; 60(5):459-67. PubMed ID: 15247961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial.
    White HD; Gallo R; Cohen M; Steg PG; Aylward PE; Bode C; Steinhubl S; Montalescot G
    Am Heart J; 2009 Jan; 157(1):125-31. PubMed ID: 19081408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of downstream high-dose tirofiban bolus among 1578 patients undergoing percutaneous coronary intervention: the Sant'ANna TIrofiban Safety study.
    Schiariti M; Saladini A; Missiroli B; Papalia F; Cuturello D; Puddu PE; Gaudio C
    J Cardiovasc Med (Hagerstown); 2010 Apr; 11(4):250-9. PubMed ID: 19952776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of heparin resistance during cardiopulmonary bypass: the effect of five different anticoagulation strategies on hemostatic activation.
    Koster A; Fischer T; Gruendel M; Mappes A; Kuebler WM; Bauer M; Kuppe H
    J Cardiothorac Vasc Anesth; 2003 Apr; 17(2):171-5. PubMed ID: 12698397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.